Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) (CardiganI)
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis
Sponsor: Botanix Pharmaceuticals
A PHASE3 clinical study on Axillary Hyperhidrosis, this trial is completed. The trial is conducted by Botanix Pharmaceuticals and has accumulated 18 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
18 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Mar 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Dec 2023 [monthly]
Completed PHASE3
▶ Show 13 earlier versions
-
Nov 2022 — Jun 2023 [monthly]
Completed PHASE3
-
Apr 2022 — Nov 2022 [monthly]
Completed PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Completed PHASE3
-
Sep 2021 — Feb 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Nov 2020 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Botanix Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .